494 Early clinical studies of intraperitoneal matrix metalloproteinase inhibitor BB94 in patients with malignant ascites
| Autor: | G.J. Beattie, John F. Smyth |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Drug
Cancer Research Pathology medicine.medical_specialty business.industry Angiogenesis Matrix metalloproteinase inhibitor media_common.quotation_subject Gastroenterology Acute toxicity Clinical trial Therapeutic index Oncology Ovarian carcinoma Internal medicine Ascites Medicine medicine.symptom business media_common |
| Zdroj: | European Journal of Cancer. 31:S106 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/0959-8049(95)95748-u |
| Popis: | BB94 is the first matrix metalloproteinase inhibitor (MPI) to enter clinical trial. In experimental systems MPIs affect tumour growth, haematogenous spread and tumour induced angiogenesis. Animal models using a human ovarian carcinoma xenograft have indicated that BB94 increases survival in mice with malignant ascites. (Cancer Research 93: 53:2087.) In a phase I study, 23 patients (P) with malignant ascites were treated with intraperitoneal BB94. The drug was well tolerated with no acute toxicity. Plasma levels of BB94 were maintained for greater than 28 days at levels above the therapeutic range in pre-clinical models. In 16 P there was no reaccumulation of ascitic fluid requiring redrainage within 28 days. 40 P were treated in phase II. Conventional criteria are hard to apply to ascites, but preliminary results suggest that 10 (25%) P responded (including 8/24 ovarian P). Clinical data on all 63 patients will be presented. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect